Latest news with #Exelixis'
Yahoo
3 days ago
- Business
- Yahoo
2 Top Stocks to Buy With Less Than $100
Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise is safe for now even as it seeks to develop newer products. 10 stocks we like better than Novo Nordisk › When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most attractive companies quickly draw attention, which bids up their share prices, it's still possible to find promising stocks for well under $100. Two great options right now are Novo Nordisk (NYSE: NVO) and Exelixis (NASDAQ: EXEL). Here's why these healthcare companies are worth investing in today. Novo Nordisk had been flying high since the beginning of the decade, until it ran into significant clinical and regulatory headwinds last year. Its challenges eventually came to a boiling point and the company parted ways with its longtime CEO, Lars Fruergaard Jørgensen, a decision it announced in mid-May. It's worth noting that Jørgensen led Novo Nordisk through a period of rapid clinical advancements, particularly within its GLP-1 segment. Novo Nordisk's top medicines, Wegovy for weight management and Ozempic for diabetes, continue to deliver excellent results. Jørgensen leaves a solid foundation for the next head of the company to build upon. Given Novo Nordisk's lineup, pipeline, and track record, the stock is likely to recover eventually. Here's one reason why. Despite recent challenges, Novo Nordisk's revenue continues to grow faster than that of almost every similarly sized pharmaceutical company. In the first quarter, net sales totaled 78.1 billion Danish kroner ($11.9 billion), a 19% increase compared to the same period last year. And on the bottom line, earnings per share were 6.53 DKK ($1), up 15% year over year. Meanwhile, Novo Nordisk should continue making moves to remain competitive in the fast-growing anti-obesity market, despite incurring some losses recently to its biggest rival, Eli Lilly. Novo Nordisk recently submitted an application to U.S. regulators requesting approval for an oral version of semaglutide, the active ingredient in Wegovy and Ozempic. Current GLP-1 therapies are typically administered by injection. Novo Nordisk also has several early-stage assets in this field, including a potential triple agonist -- a GLP-1 medicine that also mimics the action of two other gut hormones. Elsewhere, the FDA (U.S. Food and Drug Administration) accepted the company's regulatory application for Wegovy in treating metabolic dysfunction-associated steatohepatitis (MASH) and granted it priority review; it's also under review by regulatory authorities for this indication in Europe. There is only one FDA-approved medicine for MASH, despite the millions of patients affected and the condition's growing prevalence. Lastly, Novo Nordisk is making progress across its pipeline, including in other therapeutic areas, such as Alzheimer's disease, where it has upcoming data readouts. Recent headwinds notwithstanding, the company remains well- positioned to lead in diabetes and obesity care for the long term, while also making strides in other areas. The stock could still deliver superior returns to patient investors. And with shares trading for just under $71 each, $100 can get you one of them. Exelixis is an oncology specialist; its most important medicine, Cabometyx, treats some forms of liver and kidney cancer. Some investors have long been worried about Exelixis' overreliance on this drug, and with good reason. In the first quarter, Exelixis' revenue came in at $555.4 million, up 30% year over year; Cabometyx's sales came in at $510.9 million. If something were to happen to this medicine -- like generic competition -- it would be a disaster for the company. Fortunately, Exelixis fended off this threat last year with a significant win in a legal battle against a generic-drug manufacturer, which should keep its cheaper competitor off the market until 2030. Still, Exelixis has continued to grind out indications for its crown jewel. One of the latest was in treating metastatic, well-differentiated pancreatic neuroendocrine tumors, a nod it received in March. Cabometyx has long been one of the top-prescribed cancer medicines of its kind in renal cell carcinoma (kidney cancer), and additional indications have helped it continue to grow its sales. Exelixis should maintain that momentum through the end of the decade. Meanwhile, it's developing other cancer medicines. It tends to target areas of the field with high unmet need, such as metastatic colorectal cancer. Despite being the second leading cause of cancer death worldwide, colorectal cancer is highly treatable when caught early -- but once it has metastasized, five-year survival rates drop. Exelixis is developing zanzalintinib to address this problem. The medicine is being tested in other clinical trials as well. Exelixis' revenue and earnings should maintain a solid upward trajectory as it secures more clinical and regulatory wins. That's how the stock can deliver strong returns. Shares are trading for about $43, so you can grab two of them with $100. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,263!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Exelixis, and Novo Nordisk. The Motley Fool has positions in and recommends Exelixis. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Top Stocks to Buy With Less Than $100 was originally published by The Motley Fool
Yahoo
23-05-2025
- Business
- Yahoo
Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business
Exelixis, Inc.'s (NASDAQ:EXEL) strong earnings report was rewarded with a positive stock price move. We have done some analysis, and we found several positive factors beyond the profit numbers. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking. Exelixis has an accrual ratio of -0.11 for the year to March 2025. That implies it has good cash conversion, and implies that its free cash flow solidly exceeded its profit last year. Indeed, in the last twelve months it reported free cash flow of US$772m, well over the US$643.6m it reported in profit. Exelixis shareholders are no doubt pleased that free cash flow improved over the last twelve months. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. As we discussed above, Exelixis has perfectly satisfactory free cash flow relative to profit. Because of this, we think Exelixis' earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at an extremely impressive rate over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example - Exelixis has 1 warning sign we think you should be aware of. Today we've zoomed in on a single data point to better understand the nature of Exelixis' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Why Exelixis Stock Is Skyrocketing Today
Exelixis handily beat Q1 revenue and earnings estimates. The drugmaker also increased its full-year revenue guidance by $100 million. Exelixis could have more catalysts on the way later this year. 10 stocks we like better than Exelixis › Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening. Exelixis reported Q1 revenue of $555.4 million, up 30.6% year over year. This result handily topped the consensus revenue estimate of $503 million. The company posted net income of $159.6 million, or $0.55 per diluted share, based on generally accepted accounting principles (GAAP). Non-GAAP earnings were $179.6 million, or $0.62 per diluted share. This reflected a significant improvement from non-GAAP earnings of $52 million, or $0.17 per diluted share, in the prior-year period. It also blew past Wall Street's average Q1 adjusted earnings estimate of $0.42 per share. Investors like it anytime a company beats top- and bottom-line quarterly estimates, as Exelixis did in Q1. However, what they really loved in this case was Exelixis' full-year guidance. The company raised its full-year revenue outlook to a range of $2.25 billion to $2.35 billion from the previous forecast of between $2.15 billion and $2.25 billion. This $100 million guidance increase was the result of accelerating demand for Exelixis' flagship cancer drug, Cabometyx. Don't be surprised by further guidance hikes later this year. CEO Michael Morrissey said in the Q1 earnings press release that the company's team quickly shifted into action to launch Cabometyx in the advanced neuroendocrine tumors (NET) indication "within hours of receiving U.S. regulatory approval in late March." He added, "We are very pleased with the initial reception and plan to provide further updates to our 2025 financial guidance as we build momentum on the NET launch and gain further clarity on additional revenue opportunities for 2025." Exelixis could have more good news on the way as well. The company expects to report results from pivotal clinical studies evaluating zanzalintinib in treating colorectal cancer and non-clear cell renal cell carcinoma in the second half of 2025. With these near-term potential positive catalysts and continued strength for Cabometyx, I think Exelixis remains a good biotech stock for aggressive investors to buy. Before you buy stock in Exelixis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,951!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $796,353!* Now, it's worth noting Stock Advisor's total average return is 948% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Exelixis. The Motley Fool has a disclosure policy. Why Exelixis Stock Is Skyrocketing Today was originally published by The Motley Fool
Yahoo
14-05-2025
- Business
- Yahoo
Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply
Exelixis recently announced its impressive first-quarter earnings for 2025, with revenue and net income showing substantial growth. This financial performance, coupled with the FDA approval of CABOMETYX for new indications, likely contributed to the company's 12.65% share price increase over the last quarter. The company's share repurchase program announcement also adds potential upward pressure, reflecting confidence in its future prospects. Given the broader market's 12% annual increase and recent 4% rise, Exelixis's price movement aligns well with overall market trends, with its strong earnings and strategic product advancements adding supportive momentum. Be aware that Exelixis is showing 1 possible red flag in our investment analysis. This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. Exelixis's recent FDA approval and strong earnings performance have set a bullish investors' narrative, aligning with analysts' positive projections for revenue and earnings growth. Over the past three years, the company's total shareholder return was very large at 78.59%, indicating strong historical performance. In comparison, over the past year, Exelixis's stock outperformed the US Market, which returned 11.5%. This past performance suggests resiliency and an ability to drive growth, factors that may further encourage investor confidence as the company expands its cabozantinib indications and accelerates its Phase I pipeline development. The approval and increased indications of CABOMETYX, combined with potential revenue growth driven by new oncology franchises, could significantly enhance Exelixis's revenue and earnings projections. Analysts forecast a revenue increase of 9.7% annually, with earnings expected to reach US$943 million by 2028. These developments support the recent strategic decisions, such as the share repurchase program, which may positively impact earnings per share by reducing outstanding shares. The current share price of US$36.86 shows a marginal discount of approximately 3.1% to analysts' consensus price target of US$38.05, reflecting market confidence in Exelixis being fairly valued at present. These projections underline the company's ambition to solidify its market position while highlighting underlying business challenges such as rising costs and competitive pressures. Assess Exelixis' future earnings estimates with our detailed growth reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:EXEL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
14-05-2025
- Business
- Yahoo
Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply
Exelixis recently announced its impressive first-quarter earnings for 2025, with revenue and net income showing substantial growth. This financial performance, coupled with the FDA approval of CABOMETYX for new indications, likely contributed to the company's 12.65% share price increase over the last quarter. The company's share repurchase program announcement also adds potential upward pressure, reflecting confidence in its future prospects. Given the broader market's 12% annual increase and recent 4% rise, Exelixis's price movement aligns well with overall market trends, with its strong earnings and strategic product advancements adding supportive momentum. Be aware that Exelixis is showing 1 possible red flag in our investment analysis. This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. Exelixis's recent FDA approval and strong earnings performance have set a bullish investors' narrative, aligning with analysts' positive projections for revenue and earnings growth. Over the past three years, the company's total shareholder return was very large at 78.59%, indicating strong historical performance. In comparison, over the past year, Exelixis's stock outperformed the US Market, which returned 11.5%. This past performance suggests resiliency and an ability to drive growth, factors that may further encourage investor confidence as the company expands its cabozantinib indications and accelerates its Phase I pipeline development. The approval and increased indications of CABOMETYX, combined with potential revenue growth driven by new oncology franchises, could significantly enhance Exelixis's revenue and earnings projections. Analysts forecast a revenue increase of 9.7% annually, with earnings expected to reach US$943 million by 2028. These developments support the recent strategic decisions, such as the share repurchase program, which may positively impact earnings per share by reducing outstanding shares. The current share price of US$36.86 shows a marginal discount of approximately 3.1% to analysts' consensus price target of US$38.05, reflecting market confidence in Exelixis being fairly valued at present. These projections underline the company's ambition to solidify its market position while highlighting underlying business challenges such as rising costs and competitive pressures. Assess Exelixis' future earnings estimates with our detailed growth reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:EXEL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
